Valley wants our patients and community to be on the alert against medical billing scams. Learn how to protect yourself and your personal information from scammers posing as hospital representatives.
Read MoreComparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Objective
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low-risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.
Study Arms
- Active Comparator: Guideline Concordant Care
- Experimental: Active Surveillance
Eligibility
- New diagnosis of DCIS without invasive cancer; date of diagnosis defined as the date of the first pathology report that diagnosed the patient with DCIS
- Unilateral, bilateral, unifocal, or multifocal DCIS
- ADH/borderline DCIS
- A patient who has had a lumpectomy with positive margins as part of their treatment for a current DCIS diagnosis is eligible (post-excision mammogram required at enrollment to establish a new baseline)
- No previous history of breast cancer (DCIS or invasive cancer) in either breast prior to current DCIS diagnosis
- 40 years of age or older at time of DCIS diagnosis
- ECOG performance status 0 or 1
- No contraindication for surgery
NCT ID
NCT02926911